Should I get a comprehensive genomic panel for Small Bowel Cancer

Genomic Testing for Small Bowel Cancer: What You Should Know

This is an excellent question, and the answer is yes—comprehensive genomic testing is now recommended for patients with small bowel adenocarcinoma (SBA). Let me explain why this matters for your care.

Why Genomic Testing is Important for SBA

According to the NCCN Guidelines for Small Bowel Adenocarcinoma (Version 4.2025), universal testing for certain genetic markers is now standard practice. Here's what makes SBA unique:

SBA has a distinct genetic profile compared to other gastrointestinal cancers like colorectal cancer. This means:

• SBA tumors have higher rates of important biomarkers that can guide treatment decisions
• Certain genetic changes appear more frequently in SBA than in similar cancers
• These findings can directly impact which treatments your oncologist recommends

What Tests Should Be Done

The NCCN Guidelines recommend that all newly diagnosed SBA patients receive:

Essential Testing (Universal Recommendation)

1. MMR/MSI Testing (Mismatch Repair or Microsatellite Instability)

   • This is the most critical test for SBA patients
   • Identifies if your tumor has deficient MMR (dMMR) or MSI-high (MSI-H) status
   • Why it matters: If positive, you may be eligible for immunotherapy (checkpoint inhibitor drugs like pembrolizumab or nivolumab) even as a first-line treatment
   • Also helps identify if you might have Lynch syndrome, a hereditary cancer condition

2. BRAF V600E mutation testing (for metastatic/advanced disease)

   • Found in about 5-10% of SBA cases
   • If present, targeted therapy with dabrafenib plus trametinib may be an option

3. HER2 amplification testing (for metastatic/advanced disease)

   • Emerging importance in SBA
   • Targeted therapies like trastuzumab deruxtecan may be beneficial

Consider Testing (Recommended)

• Tumor Mutational Burden (TMB) - approximately 9-11% of SBA tumors are TMB-high, which is significantly higher than colorectal cancer (4.3%)
• POLE/POLD1 mutations - associated with ultra-hypermutated phenotype and immunotherapy response
• KRAS, NTRK, RET mutations - for identifying additional targeted therapy options

Why This Matters: Real Treatment Impact

Here's the practical difference genomic testing makes:

Example 1 - MMR/MSI-H Status: If your tumor shows dMMR/MSI-H, you may qualify for checkpoint inhibitor immunotherapy as a first-line treatment option, rather than waiting until chemotherapy fails. The NCCN Guidelines specifically note this is "relevant for treatment selection in stage IV disease."

Example 2 - TMB-High Status: If your tumor has high tumor mutational burden, pembrolizumab (an immunotherapy drug) becomes a potential option, even if your tumor doesn't have MSI-H status.

Example 3 - BRAF V600E Mutation: This opens the door to targeted therapy combinations that work differently than standard chemotherapy.

Important Considerations

Testing Location Matters:

• Tests must be performed in CLIA-certified laboratories (Clinical Laboratory Improvement Amendments)
• This ensures accuracy and that results are properly documented in your [ID removed] Your oncologist can order these tests through accredited labs

Timing:

• Ideally done at diagnosis or before starting treatment
• Can also be done on metastatic tumors if initial testing wasn't comprehensive

Cost:

• Most insurance plans cover genomic testing for cancer patients
• Ask your oncology team about coverage before testing

Questions to Ask Your Oncologist

1. "Has my tumor been tested for MMR/MSI status? If not, can we order this test?"
2. "What other biomarkers should be tested given my stage and situation?"
3. "Which of these test results would change my treatment recommendations?"
4. "Are there any clinical trials I might qualify for based on my tumor's genetic profile?"
5. "Will these results be shared with my [ID removed] all my doctors can see them?"

The Bottom Line

According to the NCCN Guidelines, comprehensive genomic testing—particularly MMR/MSI testing—is now considered standard of care for small bowel adenocarcinoma. The unique genetic landscape of SBA means these tests can reveal treatment options that might not be considered for other GI cancers.

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.